Atlas Trials

A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours

Clinical trial NCT02521844 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02521844
Sponsor
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Solid Tumors
Start date
2015-10-01
Primary completion
2024-10-31
Enrollment
89

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.